Salute e Benessere
Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca
Discover which therapies are expected to grab the radioligand therapies market share @
The radioligand therapies market has witnessed significant dynamics driven by advancements in oncology and nuclear medicine. One of the key drivers of market growth is the . As cancer rates rise, there is a growing demand for effective therapies that can improve patient outcomes and quality of life. Radioligand therapies, such as those for prostate cancer or somatostatin receptors for neuroendocrine tumors, have shown promising results in clinical trials, fueling their adoption in clinical practice.
Moreover, in imaging and radiopharmaceutical production have bolstered the development and commercialization of radioligand therapies. The has enhanced the diagnosis and staging of cancers, facilitating the selection of appropriate patients for radioligand therapy.
Market dynamics also include , which play a critical role in the adoption and accessibility of radioligand therapies. Regulatory agencies worldwide are increasingly recognizing the potential of these therapies, expediting their approval processes for various cancer types. Furthermore, are essential in ensuring that patients can afford these innovative treatments.
Looking forward, are expected to drive further advancements in radioligand therapies. These partnerships facilitate , ultimately expanding the therapeutic landscape for cancer patients globally. As the field continues to evolve, ongoing research into novel targets and isotopes promises to unlock new opportunities for personalized and effective cancer treatment strategies.
Radioligand therapies are a burgeoning treatment modality for diverse cancers. They demonstrate efficacy in enhancing progression-free survival and quality of life for neuroendocrine tumors, and in improving overall survival for metastatic castration-resistant prostate cancer, prompting their inclusion in cancer care guidelines. Moreover, RLT holds promise for treating aggressive or rare cancers, especially metastatic cases lacking effective therapies.
Several RLTs, including , are FDA-approved. LUTATHERA represents a significant breakthrough as the inaugural treatment sanctioned specifically for pediatric patients diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This approval signals a new prospect for young individuals grappling with this uncommon form of cancer. Moreover, LUTATHERA has also been endorsed in Europe for adults with unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs, and in Japan for SSTR-positive NETs.
LUTATHERA is a radioactive medication designed to target somatostatin receptors found on certain tumor cells. By binding to these receptors and entering the cells, the drug delivers radiation that can effectively damage the tumor cells.
PLUVICTO represents the first FDA-approved targeted radioligand therapy for eligible patients suffering from mCRPC, integrating a targeting molecule (ligand) with a therapeutic radioisotope. The active component of lutetium Lu 177 vipivotide tetraxetan is the radionuclide lutetium-177, which is coupled with a moiety that binds to PSMA, a transmembrane protein expressed in prostate cancer, including mCRPC. Once lutetium Lu 177 vipivotide tetraxetan attaches to PSMA-expressing cells, the beta-minus emissions from lutetium-177 deliver radiation to both PSMA-expressing cells and neighboring cells, inducing DNA damage that may result in cell death. PLUVICTO achieved sales exceeding USD 950 million .
NOVARTIS currently offers two RLTs globally, with multiple others in development and over 15 clinical trials underway or planned. The sector has seen acquisitions, such as AstraZeneca's acquisition of Fusion Pharmaceutical, advancing its RLT FPI-2265 into phase II/III clinical trials.
Learn more about the FDA-approved radioligand therapies @
Several key players, including , and others, are involved in developing drugs for radioligand therapies for various indications such as prostate cancer, pancreatic cancer, and others.
targets prostate-specific membrane antigen, found in over 85% of prostate cancer cells. Due to its high specificity for this antigen, the radioisotope selectively targets these cancer cells. Upon binding to the cancer cell, the radioisotope is taken up internally, where its radioactive properties disrupt the cancer cell's DNA strands, effectively killing it.
holds exclusive global commercialization rights (excluding specific Asian territories) for , a potential radioligand therapy utilizing PSMA-targeted ligand PSMA-I&T paired with the beta-emitting radioisotope no-carrier-added lutetium-177. The therapy, developed by POINT, gained Fast Track designation from the FDA in April 2023 for treating mCRPC.
Other radioligand therapies in the pipeline include
The anticipated launch of these emerging therapies are poised to transform the radioligand therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Radioligand Therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about radioligand therapies clinical trials, visit @
Radioligand therapies (RLT) represent a specialized form of targeted nuclear medicine designed to detect and treat diseases like cancer. These therapies deliver radiation specifically to cancer cells that exhibit particular targets. RLT marks a significant stride in precision oncology, providing a focused approach to combating cancer.
RLT involves two main components: a radioisotope and a cell-targeting compound (ligand), chemically linked together. The radioisotope emits radiation that targets and destroys specific cancer cells, while the ligand attaches to cells expressing these specific targets, guiding the radioisotope to its intended destination.
Therapeutic radioisotopes are typically produced in dedicated nuclear reactors or generators, and then transported to production facilities where they are combined with the cell-targeting compound. The final product is packaged in vials, undergoes rigorous quality testing, is secured in special lead-shielded containers, and finally shipped directly to hospitals or clinics as a ready-to-administer therapy.
Discover more about radioligand therapies in development @
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key nuclear medicine companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key GEP-NETs companies including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key neuroendocrine tumors companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key neuroendocrine tumors companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679